Indivior Considers Moving Primary Listing to the U.S. as it Reports Fourth-Quarter Profit
Pharmaceutical company, Indivior, announced on Thursday that it is considering moving its primary listing from the U.K. to the U.S. by 2024, as it reported a fourth-quarter pretax profit. The potential move comes as Indivior aims to align its listing with its focus on the U.S., where its proprietary products are centered.
Indivior stated that the shift would attract more U.S. investors and analysts, while also reflecting the increasing number of U.S. shareholders, who currently make up nearly 50% of the company’s share capital ownership. The company has initiated consultations with shareholders to discuss the potential move and gather input.
In the fourth quarter, Indivior reported a pretax profit of $61 million, compared to a pretax loss of $256 million in the same period the previous year. For the full year of 2023, the company reported a pretax profit of $1 million, an improvement from the pretax loss of $95 million in 2022.
The net revenue for the fourth quarter increased to $293 million, up from $241 million in the previous year. Additionally, the overall revenue for 2023 rose to $1.09 billion, compared to $901 million in 2022. Indivior specifically noted a 26% increase in fourth-quarter net revenue in the U.S., totaling $249 million, and a 25% increase in overall 2023 net revenue in the U.S., reaching $912 million.
Looking ahead, Indivior anticipates net revenue in the range of $1.24 billion to $1.33 billion for 2024. The company remains focused on capitalizing on growth opportunities in the U.S. market, which is expected to drive further expansion and profitability.
Indivior’s potential listing move to the U.S. reflects its strategic vision and desire to maximize its presence in the American pharmaceutical industry. The company aims to leverage its success and attract even more investors and analysts as it positions itself for future growth.
Analyst comment
Positive news: Indivior considers moving primary listing to the U.S. and reports fourth-quarter profit.
As an analyst: Indivior’s potential move to the U.S. market and its profitability in the fourth quarter indicate a positive outlook for the company. The shift is likely to attract more investors and contribute to further growth and profitability in the future.
